- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04822038
Immunomodulating Effects of Supplementation With 25-OH Vitamin D (SCLERODERMA)
Immunomodulating Effects of Supplementation With 25 oh Vitamin D in Adults With Scleroderma and Hypovitaminosis D
Introduction. The thickening fibrotic of the skin in systemic sclerosis (SSc) could reduce endogenous availability of Vitamin D by sun exposition. Vitamin D hypovitaminosis have been described in high prevalence in autoimmune disease as SSc. The cholecalciferol contributes to improve the balance TH1/Th2/Treg in favor anti-inflammation and anti-fibrotic profile.
Aim. to analyze the effect(s) of short-term cholecalciferol supplementation on cytokine profile in Th1, Th2, and Treg cells subpopulations in SSc patients.
Method. Randomized clinical trial conduct in patients with SSc (ACR-EULAR 2015) who signed informed consent. General characteristics, severity of organ involvement scored by Medsger disease severity scale (MsDSS) and cytokine Th1, Th2 and Treg will be determinate.
All data will be analyzed using SPSS software. It will be used parametric statistics for normally distributed variables and nonparametric statistics for free distribution.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study will be carried out with prior authorization from the Local Research and Ethics Committee. Patients entitled to our healthcare services and complying with screening criteria will be included.
Patients with scleroderma included in our database will be invited to participate in the study through a telephone call. Patients complying with the screening criteria and accepting to participate in the study will be given a date.
On the day of the interview, they will be given the informed consent form. Once it has been signed, they will be asked to complete clinical recorder and serum samples were collected for biochemical determinations including Vitamin D status.
Once patients have completed the initial evaluations, another visit will be scheduled two weeks later. Patients with hypovitaminosis D result will be randomly assigned to one of two groups: Group 1. Vitamin D3 supplementation and Group 2. Dietary recommendations. Two groups given instructions to follow dietary recommendations or to receive vitamin D3 supplementation and complete the medical measurements. Additionally, the investigators included SSc patients with vitamin D sufficiency and another one with healthy donors.
On the second visit (four weeks later), clinical data and the following parameters will be recorded: calcium, phosforus, parathyroid hormone by quimioluniscencia 25-hydroxyvitamin D serum status by ELISA, intracellular cytokine (IL-2, INF-γ, IL-4 and IL-10) production from Th1, Th2 and Treg lymphocytes by flow cytometry.
Group 1. Daily oral dosages of 5,000 UI vitamin D3 during 4 weeks.
Group 2. Dietary recommendations according to the recommendations for normal daily intake of vitamin D in food during 4 week.
And additionally, the investigators are including SSc group with vitamin D sufficiency and healthy donors both as comparators.
Each group will be given written instructions regarding the drug use. At the end of the supplementations another visit will be scheduled to check for treatment compliance (remaining capsules will be counted) and patients will complete the second clinical evaluations and calcium, phosforus, parathyroid hormone by quimioluniscencia 25-hydroxyvitamin D serum status by ELISA, intracellular cytokine (IL-2, INF-γ, IL-4 and IL-10) production from Th1, Th2 and Treg lymphocytes by flow cytometry. At the end the statistical analysis will be carried out.
Participants will also be asked to complete a form recording symptoms and potential adverse events.
Lymphocyte Separation Peripheral blood mononuclear cells (PBMCs) were isolated by density gradient centrifugation (Ficoll-Hypaque; Sigma-Aldrich) from freshly drawn venous blood. Intracellular cytokine production in PBMCs (1x106 cells/tube) were stimulated at 37ºC for 4h with Ionomicyn calcium salt from Streptomyces conglobates (1μg/ 1 x106 cells, Sigma-Aldrich), Brefeldin A (10μg/ 1 x106 cells, Cayman chemical company) and phorbol-12-myristate-13-acetate (PMA-25ng/1 x106 cells, Sigma-Aldrich).
Cell Surface and Intracellular Staining of T Cells PBMCs were resuspended with (PBS) phosphate-buffered saline (pH 7.2) (Thermo Fisher Scientific) and stained with monoclonal conjugated antibodies with either fluorescein isothiocynate (FITC), peridinin chlorophyll protein complex (PerCP), phyco-erythrin (PE) or allophycocyanin (APC) and directed to CD69 (L/78), CD25, CD3, CD4 (BD PharmigenTM and BD Bioscience) for 20 min. For intracellular staining of IL-4 (BD PharmigenTM), IL-2, INF-γ (BD Fast Immune), FoxP3 (Affymetrix) and IL10 (eBioscinence), cells previously were fixed using fixation buffer (BioLegend) for 20 min at room temperature followed by a washing step with permeabilization buffer (Perm/Wash Buffer BD Pharmigen TM) according to the manufacture's protocols, then staining cells were incubated with monoclonal antibody for 20 min at room temperature and resuspended in PBS buffer. Evaluation of Th1, Th2 and Treg subpopulations by flow cytometry were determinate as IL-2+ and INF-γ+ percentages expression for Th1 lymphocytes, IL-4+ for Th2, and CD25+FoxP3+IL-10+ for Treg within the CD3+CD4+ gate. Data were acquired and analyzed using a four-parameter flow cytometer FACS Calibur using ProCellQuest software (Beckman Coulter; BD Biosciences) and Flowing Software (Version 2.5.1) Cell Imaging Core .
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Mexico City, Mexico, 02990
- Instituto Mexicano del Seguro Social
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Scleroderma individuals according to 2013 American College of Rheumatology/European League against Rheumatism (ACR/EULAR 2013) classification criteria for SSc.
Exclusion Criteria:
- insufficient data to enable classification
- any acute bacterial infection
- abnormal kidney function
- comorbidity
- other chronic disease degenerative disease such as diabetes and malignancies
- subjects who received biological therapy or mycophenolate-mofetil during the previous month.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Scleroderma patients with hypovitaminosis D and dietary recommendations
Patients with scleroderma and hypovitaminosis D who receive dietary recommendations
|
Dietary recommendations based on food rich in 25 (OH) vitamin D
|
ACTIVE_COMPARATOR: Scleroderma patients with hypovitaminosis D and Vitamin D supplementation
Patients with scleroderma and hypovitaminosis D who receive Vitamin D supplementation
|
5000 UI Vitamin D3 daily by 4 weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Effects of vitamin D supplementation on the Th1, Th2 and Treg cytokine profile in adults with scleroderma and hypovitaminosis D
Time Frame: 2 years
|
To assess whether vitamin D3 supplementation modifies the proportion of cytokines inTh1 (IL-2 (%) / INF-ү (%)), Th2 (IL-4 (%)), Treg (IL-10 (%)) cells, in patients with scleroderma and hypovitaminosis D, by flow cytometry.
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Vitamin D and cirokines serum levels in scleroderma patients with hypovitaminosis D
Time Frame: 2 years
|
Measure serum levels of Th1 (IL-2 (%)/ INF-ү (%)), Th2 (IL-4 (%)), Treg (IL-10 (%)) and TGF-β in patients with scleroderma and hypovitaminosis D.
|
2 years
|
Clinical effects of vitamin D3 supplementation in patients with scleroderma and hypovitaminosis D.
Time Frame: two months from the recruitment of each individual
|
To evaluate if the supplementation with vitamin D3 and / or dietary recommendations (beginning and month), modify the symptoms in patients with scleroderma and hypovitaminosis D. Assesed with the severity of organ involvement scored by Medsger disease severity scale (from 0 (no documented involvement) to 4 (endstage disease) for each organ system.
|
two months from the recruitment of each individual
|
Association between vitamin D, Th1 (IL-2 / INF-γ), Th2 (IL-4), and Treg (IL-10).
Time Frame: 2 years
|
To evaluate the possible correlation between serum levels of vitamin D (ng/mL) with Th1, Th2 and Treg subpopulations by flow cytometry were determinate as IL-2+ and INF-γ+ percentages expression for Th1 lymphocytes, IL-4+ for Th2, and CD25+FoxP3+IL-10+ for Treg within the CD3+CD4+ gate.
Data were acquired and analyzed using a four-parameter flow cytometer FACS Calibur using ProCellQuest software (Beckman Coulter; BD Biosciences) and Flowing Software (Version 2.5.1)
Cell Imaging Core.
|
2 years
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Nutrition Disorders
- Connective Tissue Diseases
- Avitaminosis
- Deficiency Diseases
- Malnutrition
- Vitamin D Deficiency
- Scleroderma, Systemic
- Scleroderma, Diffuse
- Physiological Effects of Drugs
- Micronutrients
- Vitamins
- Bone Density Conservation Agents
- Calcium-Regulating Hormones and Agents
- Vitamin D
- Cholecalciferol
Other Study ID Numbers
- R-2014-3501-105
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vitamin D Deficiency
-
University Hospital, Clermont-FerrandTerminated
-
Federal University of Rio Grande do SulCompletedDeficiency, Vitamin DBrazil
-
Rajavithi HospitalQueen Sirikit National Institute of Child HealthCompleted
-
Universidade de Passo FundoUnknownDeficiency, Vitamin DBrazil
-
Nutrition Institute, SloveniaEuropean Regional Development Fund; Vizera d.o.o.; Frutarom Etol d.o.o.CompletedVitamin B 12 Deficiency | Vitamin d Deficiency | Protein DeficiencySlovenia
-
Wageningen UniversityDSM Nutritional Products, Inc.; Top Institute Food and NutritionCompletedElderly, Frail | Deficiency, Vitamin DNetherlands
-
University of PaviaIstituti Clinici Scientifici Maugeri SpAUnknownVitamin D Deficiency | Vitamin D3 Deficiency | Vitamin DItaly
-
Okan UniversityArçelik A.Ş.Completed
-
Brigham and Women's HospitalCompletedVitamin d Deficiency
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNot yet recruitingVitamin d DeficiencyChina
Clinical Trials on Dietary recommendations
-
ViomeSpondylitis Association of America (SAA)Terminated
-
Clinica Universidad de Navarra, Universidad de...CompletedOverweight | Microbiota | Food | Habits | SustainabilitySpain
-
Bournemouth UniversityActive, not recruiting
-
Bait Balev HospitalBen-Gurion University of the NegevUnknownNutritional Status | Continuity of Nutritional Care | Health Care UseIsrael
-
Clinica Universidad de Navarra, Universidad de...CompletedObesity | Weight Loss | ProteinSpain
-
University of FloridaCompletedTrigeminal NeuralgiaUnited States
-
University Hospital, IoanninaGreece 2021 Committee; Hellenic Stroke Organization; Municipality of North Kynouria and other collaboratorsRecruitingMyocardial Infarction | Heart Diseases | Cardiovascular Diseases | Coronary Disease | Hypertension | Diabetes Mellitus | Dyslipidemias | Peripheral Artery Disease | Cerebrovascular Disease | Stroke (CVA) or TIAGreece
-
Universität Duisburg-EssenRecruitingCancer | Chemotherapy | Acupuncture | Taste Disorders | DysgeusiaGermany
-
Carmel Medical CenterWithdrawnThe Impact of Nutritional Service in the Stone Clinic on the Patient Urine Collection Results (NUT1)Kidney Calculi | Kidney StoneIsrael
-
Hospital Universitari de BellvitgeCompletedObesity | Weight Loss | Obstructive Sleep Apnea of Adult | LifestyleSpain